The BARD score is a model to detect advanced liver fibrosis in patients with NAFLD, derived from a summation of the aspartate aminotransferase (AST)/alanine transaminase (ALT) ratio, BMI ≥ 28 kg/m2, and the presence of type 2 diabetes mellitus [11]. This evidence concerns the gene GPT and metabolic dysfunction-associated steatotic liver disease.